Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. User Boards ›
  4. The Bridge Message Board

More people died following Pfizer’s COVID-19 vac

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 126758
(Total Views: 365)
Posted On: 01/20/2022 8:00:44 AM
Posted By: Rusty
More people died following Pfizer’s COVID-19 vaccine vs. a placebo during clinical trial

Nobody can truthfully claim that Pfizer’s Wuhan coronavirus (COVID-19) vaccine has been proven by a clinical trial to save lives. Still, people are being pressured to receive the vaccine under threat of court-martial, loss of employment, denial of medical treatment and exclusion from normal life.

On Nov. 8, the Food and Drug Administration published a report updating the clinical trial results of Pfizer’s mRNA-based COVID-19 vaccine. The trial included around 44,000 people over the age of 16, equally divided into two groups. One group received the vaccine and the other a placebo.

Page 23 of the report showed that over the course of the trial, there were a total of 38 deaths among participants: 21 in the vaccinated group and 17 in the placebo group. Because the number of deaths in the vaccinated group was not significantly less than the placebo group (but is, in fact, more than the placebo group), the vaccine failed to prove itself by the standard of all-cause mortality.

All-cause mortality is the number of deaths due to any cause in both the control and treated groups of a clinical trial. This is the most reliable clinical endpoint for the evaluation of a medical treatment that is supposed to reduce mortality because it is objective and properly accounts for unanticipated effects, which may offset the anticipated benefits of a treatment.

The National Academy of Sciences published a volume that explained the evaluative advantage of all-cause mortality with many lessons from the annals of medical history. A contributor to the volume, renowned anesthetist John P. Bunker, said: “When dealing with mortality as an endpoint of treatment, all-cause mortality is ignored at the peril of the investigators and the public.”

The burden of proving statistical significance is on the vaccine, not the placebo. The primary hypothesis of the clinical trial was that the vaccine would save lives, and for the hypothesis to be upheld, the death rate in the vaccinated group had to be significantly less than that of the placebo group – which did not happen in this case.

There is currently no scientific basis for retaining the hypothesis that the administration of the Pfizer COVID-19 vaccine could save lives.

However, there are reasons besides vaccination why the COVID death rate may be higher in one society than another, including population-age distributions, vaccinations and even access to therapeutics.

The most obvious problem, however, is the reinforcing bias of the clinician, who knows whether or not the patient has been COVID-vaccinated.

Among multiple comorbidities, the clinician might be more likely to attribute the death to COVID if he or she knows that the patient is not vaccinated.

If this happens, then the clinicians in populations with a higher vaccination rate would be less likely to attribute the deaths to COVID than the clinicians in populations with lower vaccination rates.

None of the trials were designed to detect a reduction in any serious outcomes such as hospitalizations and deaths. While the vaccines are hailed to be the solution to the pandemic, clinical trials could not and did not prove that they can save lives. None of the vaccines studied were supported by concrete evidence to be able to interrupt the transmission of the virus.

Part of the reason for the lack of convincing results may be the numbers, because most people with symptomatic COVID-19 infections only experience mild symptoms, even for trials involving 30,000 or more patients.

“Hospitalizations and deaths from covid-19 are simply too uncommon in the population being studied for an effective vaccine to demonstrate statistically significant differences in a trial of 30,000 people.

The same is true regarding whether it can save lives or prevent transmission.

The trials are not designed to find out,” said Peter Doshi, associate editor at the global healthcare knowledge publication, BMJ.


https://sciencefraud.news/2021-12-10-pfizer-v...ives.html#


(1)
(0)








Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us